A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine

Allergan

Status and phase: Completed; Phase 4

Conditions: Migraine Disorders

Treatments: Biological: botulinum toxin Type A

Study type: Interventional

Funder types: Industry

Identifiers

NCT02147561

191622-148

Details and patient eligibility

About

This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.

Enrollment: 280 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ethnically Korean with a diagnosis of chronic migraine

Exclusion criteria

• Anticipated need for botulinum toxin treatment for any reason other than chronic migraine during the study
• Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

280 participants in 1 patient group

botulinum toxin Type A

Experimental group

Description:

Botulinum toxin Type A injected across specific head and neck muscles on Day 0.

Treatment:

Biological: botulinum toxin Type A